The Department of Health and Human Services (HHS) launched a web-based treatment locator to help healthcare providers and patients find outpatient locations offering COVID-19 treatment with monoclonal antibody therapeutics, according to a press release.
The U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for the medications to treat patients with mild or moderate COVID-19 who are at high risk of developing severe symptoms and requiring hospitalization.
To ensure the therapeutic treatments are not in short supply, HHS said it has agreements in place with Regeneron to purchase approximately 300,000 treatment courses of the company's casirivimab/imdevimab and with Eli Lilly and Company to purchase approximately 3 million treatment courses of the bamlanivimab.
As of January 6, HHS said it had had allocated more than 641,000 patient treatment courses to states and territories, which subsequently directed delivery of the medications to more than 3,700 locations. Approximately 75 percent of the treatment courses allocated to date remain available for use.
The COVID-19 therapeutics distribution page shows locations where these monoclonal antibody therapeutics have been delivered, including the facility name and address and which monoclonal antibody therapeutic has been delivered to the site. Only facilities that are open to the general public are listed. The locator does not include facilities that receive the monoclonal antibody therapeutics for outpatient treatment of specific groups, such as for patients in long-term care facilities, skilled nursing facilities, psychiatric facilities, or prisons.
States and territorial health departments must opt in to have information for facilities within their jurisdictions available in the locator. The locator launched with 22 state and territorial health departments opting in, and HHS said it is encouraging all states and territories to participate.
